Company / Operating Cash Flow
Whitehawk Therapeutics, Inc. Operating Cash Flow History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$59.5M
FY2025
5-year range
-$59.7M / -$12.7M
FY2021-FY2025
Trend
+0.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow returned to growth in FY2025 after 3 years of decline, reaching -$60M.
Based on SEC 10-K filings.
-$60M in FY2025.
Declined from -$50M to -$60M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 0.2% year-over-year.
- Peak operating cash flow was recorded in FY2019.
- Lowest operating cash flow in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$59.5M | +0.2% |
| FY2024 | -$59.7M | -20.2% |
| FY2023 | -$49.6M | -121.4% |
| FY2022 | -$22.4M | -76.5% |
| FY2021 | -$12.7M | +46.8% |
| FY2020 | -$23.9M | -310.7% |
| FY2019 | -$5.8M | +69.2% |
| FY2018 | -$18.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026